391 related articles for article (PubMed ID: 35741017)
1. The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous
Gralewska P; Gajek A; Rybaczek D; Marczak A; Rogalska A
Cells; 2022 Jun; 11(12):. PubMed ID: 35741017
[TBL] [Abstract][Full Text] [Related]
2. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
[No Abstract] [Full Text] [Related]
3. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
4. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
5. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract][Full Text] [Related]
6. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra V; Wang AT; Castroviejo-Bermejo M; Polanska UM; Palafox M; Herencia-Ropero A; Jones GN; Lai Z; Armenia J; Michopoulos F; Llop-Guevara A; Brough R; Gulati A; Pettitt SJ; Bulusu KC; Nikkilä J; Wilson Z; Hughes A; Wijnhoven PWG; Ahmed A; Bruna A; Gris-Oliver A; Guzman M; Rodríguez O; Grueso J; Arribas J; Cortés J; Saura C; Lau A; Critchlow S; Dougherty B; Caldas C; Mills GB; Barrett JC; Forment JV; Cadogan E; Lord CJ; Cruz C; Balmaña J; O'Connor MJ
Clin Cancer Res; 2022 Oct; 28(20):4536-4550. PubMed ID: 35921524
[TBL] [Abstract][Full Text] [Related]
8. Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of
Biegała Ł; Kołat D; Gajek A; Płuciennik E; Marczak A; Śliwińska A; Mikula M; Rogalska A
Cells; 2024 May; 13(10):. PubMed ID: 38786089
[TBL] [Abstract][Full Text] [Related]
9. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
[TBL] [Abstract][Full Text] [Related]
10. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
[TBL] [Abstract][Full Text] [Related]
11. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
12. Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Wethington SL; Shah PD; Martin L; Tanyi JL; Latif N; Morgan M; Torigian DA; Rodriguez D; Smith SA; Dean E; Domchek SM; Drapkin R; Shih IM; Brown EJ; Hwang WT; Armstrong DK; Gaillard S; Giuntoli R; Simpkins F
Clin Cancer Res; 2023 Aug; 29(15):2800-2807. PubMed ID: 37097611
[TBL] [Abstract][Full Text] [Related]
13. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
14.
Gupta N; Huang TT; Nair JR; An D; Zurcher G; Lampert EJ; McCoy A; Cimino-Mathews A; Swisher EM; Radke MR; Lockwood CM; Reichel JB; Chiang CY; Wilson KM; Cheng KC; Nousome D; Lee JM
Sci Transl Med; 2023 Jun; 15(701):eadd7872. PubMed ID: 37343085
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
Gupta N; Huang TT; Horibata S; Lee JM
Pharmacol Res; 2022 Apr; 178():106162. PubMed ID: 35259479
[TBL] [Abstract][Full Text] [Related]
17. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
18. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
19. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
[TBL] [Abstract][Full Text] [Related]
20. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.
George E; Kim H; Krepler C; Wenz B; Makvandi M; Tanyi JL; Brown E; Zhang R; Brafford P; Jean S; Mach RH; Lu Y; Mills GB; Herlyn M; Morgan M; Zhang X; Soslow R; Drapkin R; Johnson N; Zheng Y; Cotsarelis G; Nathanson KL; Simpkins F
JCI Insight; 2017 Jan; 2(1):e89760. PubMed ID: 28097235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
